Overview
- The Bio‑Hermes‑002 trial, led by LifeArc and the Global Alzheimer’s Platform Foundation, has enrolled 883 of 1,000 adults across the UK, US and Canada, with more than 360 completing assessments.
- Samples collected on plasma separation cards can be stored and shipped at room temperature, then analyzed for pTau217, GFAP and NfL and compared with PET, MRI and other digital and blood biomarkers.
- Investigators expect to complete the study in 2028, with recruitment designed to include substantial representation from under‑represented groups.
- Separately, the EU‑backed 2D‑BioPAD project is piloting a graphene and AI‑based device intended to read multiple Alzheimer’s biomarkers from a simple blood sample, with performance comparisons targeted by late 2026.
- In India, Mahajan Imaging & Labs launched an AI‑integrated pTAU/Aβ1‑42 blood test paired with PET/MRI pathways, which the provider says has US FDA and CDSCO clearance for use in clinical workflows.